enGene Holdings Inc.·4

Feb 3, 4:07 PM ET

Connolly Joan 4

4 · enGene Holdings Inc. · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

enGene (ENGN) CTO Joan Connolly Receives 195,000-Share Option Award

What Happened
Joan Connolly, Chief Technology Officer of enGene Holdings, was granted a derivative award (an option) covering 195,000 shares on January 30, 2026. The reported acquisition price is $0.00, meaning no cash was paid at grant. This is a grant/award for compensation purposes rather than an open-market purchase or sale.

Key Details

  • Transaction date: 2026-01-30; Form 4 filed 2026-02-03 (timely filing).
  • Security: Derivative (option) for 195,000 shares; reported acquisition price $0.00.
  • Vesting: Option vests monthly in substantially equal amounts over 48 months, subject to continued service (per footnote).
  • Shares owned after transaction: Not reported in this filing.
  • Transaction code: A = Award/Grant.

Context
Option grants are common executive compensation and are intended to align management incentives with shareholder value over time. Because this is a vesting award (not an immediate purchase or sale), it does not reflect an immediate market buy/sell decision; value is realized only as options vest and — if exercised — shares are acquired.

Insider Transaction Report

Form 4
Period: 2026-01-30
Connolly Joan
Chief Technology Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-01-30+195,000195,000 total
    Exercise: $9.53Exp: 2036-01-30Common Shares (195,000 underlying)
Footnotes (1)
  • [F1]This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Signature
/s/ Lee G. Giguere, as attorney-in-fact for the Reporting Person|2026-02-03

Documents

1 file
  • 4
    form4.xmlPrimary